MNPR FY2025 EPS Forecast Lifted by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald raised its FY2025 EPS estimate for Monopar Therapeutics to ($1.33), slightly improving from the prior estimate of ($1.35), while maintaining an "Overweight" rating on the stock.
• Multiple analysts, including Lake Street Capital and Chardan Capital, have initiated coverage or raised price targets on Monopar Therapeutics, with current consensus price target at $82.33.
• Significant insider selling occurred, with Director Christopher M. Starr selling 16,800 shares and Tactic Pharma LLC selling over 550,000 shares, representing major decreases in their stakes.

Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - Cantor Fitzgerald upped their FY2025 EPS estimates for Monopar Therapeutics in a note issued to investors on Thursday, September 25th. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will post earnings of ($1.33) per share for the year, up from their previous estimate of ($1.35). Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for Monopar Therapeutics' current full-year earnings is ($1.65) per share. Cantor Fitzgerald also issued estimates for Monopar Therapeutics' FY2026 earnings at ($2.79) EPS.

Several other equities analysts also recently issued reports on MNPR. Lake Street Capital initiated coverage on shares of Monopar Therapeutics in a report on Tuesday, September 23rd. They set a "buy" rating and a $106.00 price objective on the stock. Chardan Capital upped their price target on shares of Monopar Therapeutics from $60.00 to $85.00 and gave the company a "buy" rating in a research note on Thursday. Oppenheimer began coverage on shares of Monopar Therapeutics in a report on Wednesday, September 3rd. They issued an "outperform" rating and a $77.00 price target for the company. HC Wainwright initiated coverage on shares of Monopar Therapeutics in a report on Tuesday, August 26th. They set a "buy" rating and a $70.00 price objective on the stock. Finally, Raymond James Financial initiated coverage on Monopar Therapeutics in a research report on Tuesday, September 2nd. They issued a "strong-buy" rating and a $80.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $82.33.

Monopar Therapeutics Stock Performance

Monopar Therapeutics stock opened at $76.63 on Monday. The stock has a market cap of $472.81 million, a PE ratio of -23.01 and a beta of 1.20. The stock has a 50-day moving average of $44.46 and a two-hundred day moving average of $39.50. Monopar Therapeutics has a one year low of $4.50 and a one year high of $79.80.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.12.

Insider Buying and Selling at Monopar Therapeutics

In other Monopar Therapeutics news, Director Christopher M. Starr sold 16,800 shares of the stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $40.00, for a total transaction of $672,000.00. Following the sale, the director directly owned 5,173 shares of the company's stock, valued at approximately $206,920. This trade represents a 76.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Tactic Pharma Llc sold 550,229 shares of Monopar Therapeutics stock in a transaction dated Wednesday, September 24th. The shares were sold at an average price of $63.61, for a total value of $35,000,066.69. Following the transaction, the insider owned 272,026 shares of the company's stock, valued at $17,303,573.86. The trade was a 66.92% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 592,733 shares of company stock worth $36,700,227 over the last ninety days. 20.50% of the stock is owned by insiders.

Institutional Trading of Monopar Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. AlphaQuest LLC grew its stake in shares of Monopar Therapeutics by 46.8% during the 2nd quarter. AlphaQuest LLC now owns 1,784 shares of the company's stock worth $64,000 after purchasing an additional 569 shares during the period. Police & Firemen s Retirement System of New Jersey purchased a new stake in Monopar Therapeutics during the second quarter worth $34,000. JPMorgan Chase & Co. grew its position in Monopar Therapeutics by 1,821.0% during the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company's stock valued at $69,000 after buying an additional 1,821 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Monopar Therapeutics in the second quarter valued at $80,000. Finally, New York State Common Retirement Fund acquired a new position in shares of Monopar Therapeutics in the second quarter worth about $104,000. 1.83% of the stock is owned by institutional investors and hedge funds.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.